Search results
Results from the WOW.Com Content Network
This page was last edited on 3 February 2025, at 20:23 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
DSAT investigates incidents related to the laboratory use of select agents and toxins and refers cases to the FBI and HHS Office of Inspector General when necessary. [2] They also review experiments that are deemed "restricted experiments" because of their increased risk. [3] Samuel S. Edwin became the director of the division in 2016. [4]
The CDC has regulated the laboratories which may possess, use, or transfer select agents within the United States under the SAP since 2001. The SAP was established to satisfy requirements of the USA PATRIOT Act of 2001 and the Public Health Security and Bioterrorism Preparedness and Response Act of 2002, which were enacted in the wake of the September 11, 2001 attacks and the subsequent 2001 ...
32nd & Commercial station is a station on the Orange Line of the San Diego Trolley located in the Stockton neighborhood of San Diego, California.The stop is located in an area where the light rail temporarily breaks from its street-level tracks and runs on a separate right-of-way around the Mt. Hope and Greenwood Cemeteries.
In 2013, it provided necessary data, which addressed 10 specific biological agent knowledge gaps, to improve hazard, risk, and threat assessments. The data allowed for significant growth in the credibility of hazard and risk assessment modeling of bioterrorism scenarios for a variety of toxin threat agents, including both bacteria and viruses.
Emergent BioSolutions was founded on September 5, 1998, by Fuad El-Hibri, under the name BioPort, which had formerly operated as a state-owned entity named Michigan Biological Products Institute [4] and was privatized as Emergent BioSolutions in 2004.
[1]: 3 [n 1] As of March 2014, the company was based in San Diego, California, and consisted of a single facility. [2]: 58 Ambit made an initial public offering in May 2013, [2] and was listed on the NASDAQ exchange under the symbol "AMBI". [3] Ambit was acquired by Daiichi Sankyo in 2014 and is no longer traded on the NASDAQ exchange. [4]
BioLegend is a global developer and manufacturer of antibodies and reagents used in biomedical research located in San Diego, California. [1] It was incorporated in June 2002 and has since expanded to include BioLegend Japan KK, where it is partnered with Tomy Digital Biology Co., Ltd. in Tokyo, BioLegend Europe in the United Kingdom, BioLegend GmbH in Germany, and BioLegend UK Ltd in the ...